Do we need anti-obesity drugs? (Q38071006)

28 August 2017

1 reference

title

Do we need anti-obesity drugs? (English)

1 reference

28 August 2017

0 references

Vojtěch Hainer

1

1 reference

28 August 2017

Irena Aldhoon Hainerová

series ordinal

2

1 reference

28 August 2017

publication date

1 December 2012

1 reference

Diabetes - Metabolism: Research and Reviews

28 August 2017

published in

1 reference

28 August 2017

volume

28 Suppl 2

1 reference

28 August 2017

page(s)

8-20

1 reference

28 August 2017

1 reference

The epidemiology of obesity: the size of the problem

21 January 2018

1 reference

Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic

21 January 2018

1 reference

Management of Obesity in Adults: European Clinical Practice Guidelines

21 January 2018

1 reference

Current and future drug targets in weight management

21 January 2018

1 reference

Pharmacotherapies for obesity: past, current, and future therapies

21 January 2018

1 reference

Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies

21 January 2018

1 reference

Treatment modalities of obesity: what fits whom?

21 January 2018

1 reference

Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions.

21 January 2018

1 reference

The prevention of type 2 diabetes

21 January 2018

1 reference

Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach

21 January 2018

1 reference

One-year weight losses in the Look AHEAD study: factors associated with success

21 January 2018

1 reference

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

21 January 2018

1 reference

Randomized trial of lifestyle modification and pharmacotherapy for obesity

21 January 2018

1 reference

Cannabinoids, opioids and eating behavior: the molecular face of hedonism?

21 January 2018

1 reference

The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity

21 January 2018

1 reference

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study

21 January 2018

1 reference

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

21 January 2018

1 reference

Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects

21 January 2018

1 reference

Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients

21 January 2018

1 reference

The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists

21 January 2018

1 reference

β(3)-Adrenoceptor ligand development history through patent review

21 January 2018

1 reference

Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes

21 January 2018

1 reference

Sobetirome: a case history of bench-to-clinic drug discovery and development

21 January 2018

1 reference

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.

21 January 2018

1 reference

Effects on weight reduction and safety of short-term phentermine administration in Korean obese people

21 January 2018

1 reference

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

Weight loss is correlated with an improved lipoprotein profile in obese postmenopausal women

21 January 2018

1 reference

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis

21 January 2018

1 reference

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis

21 January 2018

1 reference

The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions

21 January 2018

1 reference

Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine

21 January 2018

1 reference

Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.

21 January 2018

1 reference

Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review

21 January 2018

1 reference

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

21 January 2018

1 reference

Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).

21 January 2018

1 reference

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial

21 January 2018

1 reference

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.

21 January 2018

1 reference

Minireview: human obesity-lessons from monogenic disorders

21 January 2018

1 reference

Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight

21 January 2018

1 reference

Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity

21 January 2018

1 reference

Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response

21 January 2018

1 reference

A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier.

21 January 2018

1 reference

Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug

21 January 2018

1 reference

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes

21 January 2018

1 reference

Obesity treatment: novel peripheral targets

21 January 2018

1 reference

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

21 January 2018

1 reference

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

Gut hormones: implications for the treatment of obesity.

21 January 2018

1 reference

Minireview: Gut peptides: targets for antiobesity drug development?

21 January 2018

1 reference

Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications

21 January 2018

1 reference

The role of pramlintide for weight loss

21 January 2018

1 reference

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

21 January 2018

1 reference

Inhibition of food intake in obese subjects by peptide YY3-36

21 January 2018

1 reference

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

21 January 2018

1 reference

PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.

21 January 2018

1 reference

Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

21 January 2018

1 reference

Ghrelin increases intake of rewarding food in rodents

21 January 2018

1 reference

Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs

21 January 2018

1 reference

The Role of Testosterone in the Etiology and Treatment of Obesity, the Metabolic Syndrome, and Diabetes Mellitus Type 2

21 January 2018

1 reference

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

21 January 2018

1 reference

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial

21 January 2018

1 reference

Reduced sleep as an obesity risk factor

21 January 2018

1 reference

Could viruses contribute to the worldwide epidemic of obesity?

21 January 2018

1 reference

An obesity-associated gut microbiome with increased capacity for energy harvest

21 January 2018

1 reference

Microbial ecology: human gut microbes associated with obesity

21 January 2018

1 reference

Balancing life-style and genomics research for disease prevention

21 January 2018

1 reference

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety e

21 January 2018

1 reference

Pharmacotherapy for obesity

21 January 2018

1 reference

7 January 2021

Central nervous system control of food intake

1 reference

7 January 2021

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

1 reference

7 January 2021

Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control

1 reference

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

7 January 2021

Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results

1 reference

7 January 2021

Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials

1 reference

7 January 2021

Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass

1 reference

7 January 2021

Neuroendocrine abnormalities in visceral obesity

1 reference

7 January 2021

1 reference

7 January 2021

Treatment of hypothalamic obesity with caffeine and ephedrine

1 reference

7 January 2021

Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.

1 reference

7 January 2021

Anti-melanocortin-4 receptor autoantibodies in obesity

1 reference

7 January 2021

Anti-obesity drugs: to be or not to be?

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.2349

1 reference

28 August 2017

1 reference